More religious-based policies expected at HHS

The opening of a “religious freedom” division within the HHS Office of Civil Rights (OCR) could just be the beginning of moves by new officials within the department to align health policy with the goals of evangelical religious groups.

POLITICO’s Dan Diamond spoke to more than a dozen current and former HHS staff members who appear troubled or at least surprised by the changes, which he framed as a strategy to weaken federal protections for abortions and transgender patients. New appointees in communications and legal positions have come from evangelical groups, such as Americans United for Life, whose former chief Charmaine Yoest is now the top spokesperson at HHS.

The strategy has involved leaving some longtime staffers out on the loop on new policies. Some workers at the HHS Center for Faith-Based and Neighborhood Partnerships only found out about the agency’s request for information on how to lower regulatory burdens on religious-affiliated healthcare organizations when it was released. HHS was later criticized for initially limiting released responses to the RFI to those favoring religious positions.

“It’s supposed to be the faith-based partnership center, not the Christian-based partnership center,” said a longtime HHS staffer.

The head of the center, Shannon Royce, was formerly the chief operating officer of the conservative Family Research Council. Speaking at an anti-abortion conference on Jan. 18, she promised attendees “good stuff is coming,” and urged anti-abortion activists to help HHS achieve its strategy.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.